Implant for reducing intraocular pressure
By designing a strip-shaped implant body with a diversion part and a porous structure, the problem of insufficient displacement and fit of the suprachoroidal drainage implant is solved, effective intraocular pressure reduction and stable attachment are achieved, and the cornea is reduced Risk of endothelial cell loss and choroidal detachment.
Patent Information
- Application Number
- CN202322304285.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-25
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2033-08-25
AI Technical Summary
The existing suprachoroidal drainage implants are prone to displace after implantation, resulting in loss of corneal endothelial cells or detachment of choroid, and their structures are not well fitted with the sclera and choroid, which increases the risk of scarring and blockage, reducing the eyes The pressure effect is limited.
Design a strip-shaped implant body including a flow guide part. The implant body has a proximal end, a distal end and an intermediate part in the longitudinal direction, a plane of the lower surface, an arc surface, and a thickness of the distal end to the intermediate part gradually Increased, with porous structure and longitudinal drainage grooves, enhance fit with the choroid and reduce the risk of displacement.
Effectively expand the suprachoroidal space, increase the outflow of water atrium, reduce intraocular pressure, reduce the risk of blockage, stabilize attachment to the choroid, and reduce the risk of corneal endothelial cell loss and choroidal detachment.
Smart Images

Figure CN221932326U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of eye implants, in particular to an implant for reducing intraocular pressure. Background Art
[0002] Glaucoma is the world's leading irreversible blinding eye disease, and with the aging of the population, the prevalence of glaucoma is increasing year by year. Intraocular pressure (IOP) is an independent risk factor for glaucoma, which leads to further damage to the optic nerve. Controlling intraocular pressure is an economical approach. There are many types of surgical treatments for glaucoma, such as laser treatment, trabeculectomy, implantation of various drainage devices and MIGS, but various surgical procedures or equipment have certain limitations. For example, the effective time of laser treatment is short, trabeculectomy has more postoperative complications, drainage devices generally have larger incisions, and MIGS has limited effect on lowering intraocular pressure.
[0003] Suprachoroidal drainage is performed by implanting a drainage device into the suprachoroidal space to expand the originally narrow suprachoroidal space, thereby increasing the outflow of aqueous humor from the suprachoroidal space and reducing intraocular pressure. Current suprachoroidal drainage implants generally protrude from the anterior chamber. If the implant is slightly displaced toward the anterior chamber, its front end contacts the cornea, increasing the risk of corneal endothelial cell loss. If the implant is displaced backward, the risk of choroidal detachment will also increase. In addition, the poor fit between the structure of the implant and the sclera and choroid will increase the scarring of the implant (causing blockage of the aqueous humor drainage channel) and displacement problems. Therefore, in order to solve the above problems, the existing implants still need to be improved and optimized. Utility Model Content
[0004] In order to solve the above-mentioned technical problems, a technical solution adopted by the utility model is to provide an implant for reducing intraocular pressure, including an implant body and a guide portion located on the implant body, the guide portion is used to discharge aqueous humor from the anterior chamber to reduce intraocular pressure, the implant body is in a strip shape, and is used to be longitudinally implanted in the suprachoroidal space, the implant body includes a proximal portion, a distal portion and a middle portion in the longitudinal direction, the proximal portion is the end of the implant close to the anterior chamber after the implant is implanted in the eye, the lower surface of the implant body is flat, the upper surface of the implant body is at least partially curved, and the thickness of at least the distal portion of the implant body to the middle portion gradually increases.
[0005] In some embodiments, the thickness of the distal end and the proximal end of the implant body gradually increases to the middle portion, and the upper surface of the implant body is generally in a convex arch shape.
[0006] In some embodiments, the implant body has a porous structure, and the guide portion includes the porous structure.
[0007] In some embodiments, the pore size of the porous structure is 10-60 μm, and the porosity is 30-70%.
[0008] In some embodiments, the guide portion further includes a longitudinal drainage groove disposed on the upper surface of the implant body along the longitudinal direction of the implant body.
[0009] In some embodiments, the portions of the implant body located on both sides of the longitudinal drainage groove form a support wall, and a transverse groove extending toward the lower surface of the implant body is provided on the upper surface of the support wall along the front-to-back direction of the support wall, and the transverse groove is connected to the longitudinal drainage groove.
[0010] In some embodiments, there are multiple transverse grooves, which are arranged regularly or irregularly along the front-to-back direction of the support wall.
[0011] In some embodiments, there is at least one longitudinal drainage groove, which is disposed in the middle position of the upper surface of the implant body.
[0012] In some embodiments, the width of the longitudinal drainage groove in the transverse direction of the implant body is 0.2 to 0.6 mm, and the depth of the longitudinal drainage groove is 0.1 to 0.4 mm.
[0013] In some embodiments, the cross-sectional shape of the longitudinal drainage groove is rectangular or semicircular; preferably, the cross-sectional shape of the transverse groove is rectangular, trapezoidal or semicircular; preferably, the maximum thickness from the upper surface to the lower surface of the implant body is 0.6±0.1mm; preferably, the minimum thickness from the upper surface to the lower surface of the implant body is 0.3±0.1mm; preferably, the width of the implant body in the transverse direction is 0.8~1.1mm; preferably, the length of the implant body in the anterior-posterior direction is 4~6mm.
[0014] The utility model has the following beneficial effects: the utility model discloses an implant for reducing intraocular pressure, comprising an implant body and a drainage portion located on the implant body, the drainage portion is used to discharge aqueous humor from the anterior chamber to reduce intraocular pressure, the implant body is in a strip shape, and is used to be longitudinally implanted in the suprachoroidal cavity, the implant body includes a proximal end portion, a distal end portion and a middle portion in the longitudinal direction, the lower surface of the implant body is plane, the upper surface of the implant body is at least partially curved, and the thickness of at least the distal end portion to the middle portion of the implant body gradually increases. The implant body can expand the originally narrow suprachoroidal cavity gap, increase the outflow of aqueous humor from the suprachoroidal cavity by the drainage portion, have a good drainage effect, are not easy to be blocked, and play a role in reducing intraocular pressure. The lower surface of the implant body is plane, the upper surface is at least partially curved, and the lower surface has a larger area of attachment with the choroid, which is conducive to stable attachment to the choroid, reducing the risk of displacement to the anterior chamber and to the choroid, avoiding exposure to the anterior chamber to touch the cornea, and reducing the risk of corneal endothelial cell loss. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 is a stereoscopic diagram of an embodiment of an implant for reducing intraocular pressure according to the utility model;
[0016] Figure 2 is a cross-sectional schematic diagram of an embodiment of an implant for reducing intraocular pressure according to the utility model;
[0017] Figure 3 is a side view of an embodiment of an implant for reducing intraocular pressure according to the utility model;
[0018] Figure 4 is a front view of an embodiment of an implant for reducing intraocular pressure according to the utility model;
[0019] Figure 5 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0020] Figure 6 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0021] Figure 7 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0022] Figure 8 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0023] Fig. 9 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0024] Fig.10 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0025] Fig.11 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0026] Fig.12 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0027] Fig.13 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0028] Fig.14 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0029] Fig.15 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0030] Fig.16 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0031] Fig.17 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0032] Fig.18 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0033] Fig.19 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0034] Fig. 20 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0035] Fig.21 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0036] Fig. 22 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0037] Fig.23 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0038] Fig.24 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0039] Fig.25 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0040] Fig.26 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0041] Fig. 27 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0042] Fig.28 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0043] Fig.29 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0044] Fig.30 are stereograms of some embodiments of implants for reducing intraocular pressure according to the utility model;
[0045] Fig.31 is a side view of some embodiments of an implant for reducing intraocular pressure according to the present invention;
[0046] Fig.32 It is a schematic diagram of the implantation position of the implant for reducing intraocular pressure of the utility model. DETAILED DESCRIPTION
[0047] In order to facilitate the understanding of the present invention, the present invention is described in more detail below in conjunction with the accompanying drawings and specific embodiments. The accompanying drawings provide preferred embodiments of the present invention. However, the present invention can be implemented in many different forms and is not limited to the embodiments described in this specification. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0048] It should be noted that, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as those commonly understood by those skilled in the art in the technical field of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in this specification includes any and all combinations of one or more related listed items.
[0049] See also Figures 1 to 31As shown, the utility model provides an implant for reducing intraocular pressure, comprising an implant body 1 and a guide portion located on the implant body 1, wherein the guide portion is used to discharge aqueous humor from the anterior chamber to reduce intraocular pressure, and the implant body is in a strip shape for longitudinal implantation into the suprachoroidal space, and the implant body 1 includes a proximal portion 101, a distal portion 103 and a middle portion 102 in the longitudinal direction, the proximal portion being an end of the implant close to the anterior chamber after implantation in the eye, and the distal portion being an end away from the anterior chamber after implantation, the lower surface of the implant body 1 being flat, the upper surface of the implant body being at least partially curved, and the thickness of at least the distal portion 103 to the middle portion 102 of the implant body 1 gradually increases.
[0050] The lower surface 3 of the implant body 1 is flat as a whole, which can make the implant body 1 and the choroid 100 fit in a larger area, and the thickness of the upper surface gradually increases from at least the distal end to the middle part to form an arc surface, which is conducive to the stable attachment of the implant to the choroid, and the upper surface 2 and the lower surface 3 of the implant body 1 can be stably fixed in the suprachoroidal space under the clamping of the sclera and the choroid respectively, reducing the risk of the implant body 1 shifting toward the anterior chamber and the choroid, avoiding exposure to the anterior chamber, and minimizing the risk of corneal endothelial cell loss.
[0051] In the present application, the lower surface 3 of the implant body 1 is flat, and the upper surface can be formed as an arched curved surface, that is, the thickness of the distal end and the proximal end to the middle part of the implant body 1 gradually increases, or only the thickness of the distal end to the middle part 102 of the implant body 1 gradually increases, that is, the upper surface 2 of the implant body is formed by a semi-arched curved surface connecting a plane. The various different embodiments of the utility model will be described and illustrated in detail below.
[0052] Specific as Figures 1 to 4 As shown, as an embodiment of an implant for reducing intraocular pressure, the implant for reducing intraocular pressure includes an implant body 1 for integral implantation in the suprachoroidal space 300 (i.e., the space between the sclera 200 and the choroid 100 of the eye), the implant body 1 is in a strip shape, the outer contour of the upper surface 2 of the implant body 1 is a convex arch, and the upper surface 2 of the implant body 1 is used to contact the sclera 200; the lower surface 3 of the implant body 1 is flat, and the lower surface 3 of the implant body 1 is used to contact the choroid 100; the front end face 5 and the rear end face 6 of the implant body 1 are both flat and perpendicular to the lower surface 3 of the implant body 1; a longitudinal drainage groove 4 is provided on the upper surface 2 of the implant body 1 along the front-to-back direction of the implant body 1 as a guide portion.
[0053] In the present invention, the front end (proximal end) of the implant body 1 refers to the end close to the anterior chamber of the eye after the implant is implanted, and the rear end (distal end) of the implant body 1 refers to the end away from the anterior chamber of the eye after the implant is implanted.
[0054] Combination Figures 1 to 4 In this embodiment, the implant body 1 is thin at the front and rear ends and thick in the middle. The implant body 1 can smoothly enter the suprachoroidal space 300 by virtue of its thin rear end (distal end) and expand the originally narrow space of the suprachoroidal space 300. After the implant body 1 is completely implanted in the suprachoroidal space 300, the middle part of the implant body 1 expands the space of the suprachoroidal space 300 to the greatest extent. Secondly, the implant body 1 can increase the outflow of aqueous humor from the suprachoroidal space 300 by virtue of the longitudinal drainage groove 4, has a better drainage effect, is not easy to cause blockage, and plays a role in reducing intraocular pressure.
[0055] In this embodiment, the implant body 1 is made of a biocompatible material, and may be an elastic non-degradable material, a super-hydrophilic material, or a super-hydrophobic material.
[0056] The implant body 1 is made of biocompatible materials, so that the implant body 1 has good biocompatibility after being implanted in the suprachoroidal space 300, and can adapt to the intraocular tissue, reduce or avoid adverse reactions to the intraocular tissue. For example, non-degradable materials with good biocompatibility, or superhydrophobic materials or superhydrophilic materials can be used. The use of non-degradable materials can reduce scarring after implantation. The implant body 1 made of superhydrophobic materials and superhydrophilic materials can inhibit excessive tissue growth (scarring) in the suprachoroidal space and the attachment of Staphylococcus aureus.
[0057] Specifically, in this embodiment and some embodiments, the implant body 1 can be made of silicone, acrylic acid, poly(ethylene-vinyl acetate) copolymer, acrylic polymer, polyethylene, polypropylene, polysulfone, poly(methyl methacrylate) (PMMA), fluoropolymer (such as polytetrafluoroethylene), polyethylene phthalate (PET or polyester), polyamide (such as nylon), polyurethane, etc.
[0058] Further, combined with Figure 2 In this embodiment, the length L of the implant body 1 in the front-to-back direction (i.e., from the proximal end to the distal end) is 5±1 mm. If the implant body 1 is too long, it is easy to enter the suprachoroidal space 300 too deeply, causing the choroid 100 to detach; if the implant body 1 is too short, it is easy to be displaced, and the anchoring effect is not good. When the length L of the implant body 1 is set within this range (4 to 6 mm), the implant body 1 is not easy to be displaced and cause the choroid 100 to detach after being implanted in the suprachoroidal space 300.
[0059] The width W1 of the implant body 1 in the transverse direction is preferably 0.8 to 1.1 mm. The width of the implant body 1 within this range is conducive to implanting the implant body 1 through a suitable surgical incision and meeting the size requirements of the longitudinal drainage groove 4. In this embodiment, the width W1 of the implant body 1 is about 1 mm, and in some other embodiments, the width W1 of the implant body 1 is about 0.8 mm, 0.9 mm or 1.1 mm.
[0060] Combination Figure 3 In this embodiment, the maximum thickness H1 from the upper surface 2 to the lower surface 3 of the implant body 1 is 0.6±0.1 mm; the maximum thickness H1 of the implant body 1 is located in the middle part of the implant body 1 (i.e., the top position of the arch). Within the range of the maximum thickness H1, the implant body 1 can both open the gap of the suprachoroidal space 300 and will not cause detachment of the choroid 100.
[0061] The minimum thickness H2 from the upper surface 2 to the lower surface 3 of the implant body 1 is 0.3±0.1mm. The minimum thickness H2 of the implant body 1 is located at the front and rear ends of the implant body 1, and is smoothly transitioned to the middle part of the implant body 1; within the range of the minimum thickness H2, the front end of the implant body 1 can open the connection between the suprachoroidal space 300 and the anterior chamber, allowing the aqueous humor to flow smoothly from the anterior chamber.
[0062] like Figure 4 As shown, in this embodiment, there is at least one longitudinal drainage groove 4, which is arranged in the middle position of the upper surface 2 of the implant body 1. In some embodiments, there are multiple longitudinal drainage grooves 4, which are evenly distributed on the upper surface 2 of the implant body 1; or in some embodiments, the upper surface 2 and the lower surface 3 of the implant body 1 are both provided with longitudinal drainage grooves 4.
[0063] In the present application, the width W2 of the longitudinal drainage groove 4 in the transverse direction of the implant body 1 is 0.2 to 0.6 mm. The specific value of the width W2 of the longitudinal drainage groove 4 can be adjusted according to the implant size and the aqueous humor drainage effect. In some embodiments, the width W2 of the longitudinal drainage groove 4 is 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm or 0.6 mm. Please refer to Figure 2 , Figure 6 , Figure 7 , Fig.10 , Fig.13 , Fig.16 , Fig.19 , Fig. 22 , Fig.25 , Fig.28 , the width W2 of the longitudinal drainage groove 4 is 0.3 mm, referring to Figure 5 , Figure 8 , Fig.11 , Fig.14, Fig.17 , Fig. 20 , Fig.23 , Fig.26 , the width of the longitudinal drainage groove 4 is 0.5 mm.
[0064] Further, such as Figure 1 As shown, in some embodiments, the cross-sectional area of the longitudinal drainage groove 4 gradually increases in the direction from the front end of the implant body 1 to the middle part of the implant body 1, that is, the cross-sectional area of the longitudinal drainage groove 4 tends to gradually increase from the front end to the middle part of the implant body 1; the cross-sectional area of the longitudinal drainage groove 4 gradually increases in the direction from the rear end of the implant body 1 to the middle part of the implant body 1, that is, the cross-sectional area of the longitudinal drainage groove 4 also tends to gradually increase from the rear end to the middle part of the implant body 1.
[0065] In the present application, the depth range of the longitudinal drainage groove 4 in the up and down directions is preferably 0.1 to 0.4 mm. When the bottom of the longitudinal drainage groove 4 is parallel to the lower surface 3 of the implant body 1, since the outer contour of the upper surface of the implant body 1 is a convex arch, it should be understood that the depth of the longitudinal drainage groove 4 gradually increases in the direction from the front end of the implant body 1 to the middle part of the implant body 1, and the depth of the longitudinal drainage groove 4 gradually increases in the direction from the rear end of the implant body 1 to the middle part of the implant body 1, that is, the depth of the longitudinal drainage groove 4 near the middle part of the implant body 1 (that is, the top position of the arch) is the deepest. In the present embodiment, the depth of the longitudinal drainage groove 4 at this location is 0.4 mm.
[0066] Please refer to Figure 4 In this embodiment, the cross-sectional shape of the longitudinal drainage groove 4 is a rectangle. In other embodiments, the cross-sectional shape of the longitudinal drainage groove 4 can also be a semicircle or other shapes, such as referring to Figure 7 As shown, the cross-sectional shape of the longitudinal drainage groove 4 is semicircular.
[0067] Further, in this embodiment, the bottom of the longitudinal drainage groove 4 is parallel to the lower surface 3 of the implant body 1. In some other embodiments, the bottom of the longitudinal drainage groove 4 is slightly inclined downward from front to back, so that the rear end of the longitudinal drainage groove 4 is lower than the front end of the longitudinal drainage groove 4, which is conducive to the diversion of aqueous humor from the suprachoroidal space 300.
[0068] like Figure 6 As shown, in some embodiments, a flow regulator 7 is provided in the longitudinal drainage groove 4. The flow regulator 7 includes a transverse baffle 8 that can close the cross section of the longitudinal drainage groove 4, and the transverse baffle 8 is permanently fixedly connected or non-permanently fixedly connected (for example, detachably connected) to the longitudinal drainage groove 4; the setting position and number of the transverse baffle 8 can be adjusted according to actual needs.
[0069] A flow-conducting hole 9 for conducting aqueous humor is arranged on the transverse baffle 8, and a flow-regulating piece 10 which can close or conduct the flow-conducting hole 9 is connected in the flow-conducting hole 9; the flow-regulating piece 10 closes the entire flow-conducting hole 9 when in a closed state; the flow-regulating piece 10 is in an open state, and the flow-conducting hole 9 is conducted, and aqueous humor can flow from one side of the flow-conducting hole 9 to the other side. In this embodiment, the closing or conducting of the flow-regulating piece 10 by the flow-regulating piece 10 is controlled by the pressure of aqueous humor. When the pressure of aqueous humor is low, the flow-regulating piece 10 closes the flow-conducting hole 9, and aqueous humor cannot pass through the flow-conducting hole 9, which can avoid the occurrence of low intraocular pressure caused by continuous discharge of aqueous humor; when the pressure of aqueous humor is high, the flow-regulating piece 10 flips open under the pressure of aqueous humor, and no longer closes the flow-conducting hole 9, and aqueous humor passes through the flow-conducting hole 9.
[0070] In some embodiments, the force required to open the flow regulating plate 10 can be set as a first critical force. When the aqueous humor pressure is lower than the first critical force, the flow regulating plate 10 closes the conduction hole 9; when the aqueous humor pressure is higher than the first critical force, the flow regulating plate 10 opens and conducts the conduction hole 9.
[0071] Furthermore, the flow-conducting hole 9 is adapted to the flow regulating piece 10, and the flow regulating piece 10 and the flow-conducting hole 9 are movably connected or elastically connected, so that the flow regulating piece 10 can be flipped or the flow regulating piece 10 can be switched between an open state and a closed state; in a preferred embodiment, the flow regulating piece 10 is made of a biocompatible elastic material, which has a certain elastic recovery and can be switched between an open state and a closed state according to the pressure of the aqueous humor.
[0072] The shape of the flow-conducting hole 9 is rectangular, circular, semicircular, triangular, or other shapes such as a rectangular upper part and a semicircular lower part.
[0073] In some embodiments, the flow regulator includes at least one transverse baffle (not shown) that can close the cross section of the longitudinal drainage groove 4, and the location and number of the transverse baffle can be adjusted according to actual needs. One end or one side of the transverse baffle is connected to the longitudinal drainage groove 4 through an elastic recovery member. When the pressure of the aqueous humor is relatively low, the transverse baffle automatically closes the longitudinal drainage groove 4 under the action of the elastic recovery member, and the aqueous humor cannot flow in the longitudinal drainage groove 4, which can avoid the occurrence of low intraocular pressure caused by continuous discharge of the aqueous humor; when the pressure of the aqueous humor is relatively high, the transverse baffle rotates under the pressure of the aqueous humor and no longer closes the longitudinal drainage groove 4, and the aqueous humor can flow in the longitudinal drainage groove 4.
[0074] In some embodiments, the force required to open the transverse baffle is the second critical force. When the aqueous humor pressure is lower than the second critical force, the transverse baffle closes the longitudinal drainage groove 4; when the aqueous humor pressure is higher than the second critical force, the transverse baffle opens and connects the longitudinal drainage groove 4.
[0075] The elastic recovery member may be a component with an automatic recovery function such as a micro spring. In some other embodiments, the flow regulator includes a first transverse baffle and a second transverse baffle arranged on the left and right sides of the longitudinal drainage groove, the first transverse baffle and the second transverse baffle are respectively connected to the groove wall of the longitudinal drainage groove through the elastic recovery member, and the first transverse baffle and the second transverse baffle jointly close or conduct the longitudinal drainage groove.
[0076] In some other embodiments, in order to make the flow regulator 7 more responsive to changes in aqueous humor pressure, the flow regulator 7 is disposed at the deepest part of the longitudinal drainage groove 4, that is, in the longitudinal drainage groove 4 near the middle part (that is, the top part of the arch) of the implant body 1, and at the same time, the cross-section of the longitudinal drainage groove 4 tends to gradually decrease from the front end to the middle part of the implant body 1; the cross-sectional area of the longitudinal drainage groove 4 also tends to gradually decrease from the rear end of the implant body 1 to the middle part of the implant body 1, that is, the cross-sectional area of the drainage groove at the position of the flow regulator 7 is the smallest, so that the pressure of the aqueous humor reaching the flow regulator 7 can be increased, and the flow regulator 7 can respond more sensitively to changes in aqueous humor pressure.
[0077] like Figure 8 As shown, the portions of the implant body 1 located on both sides of the longitudinal drainage groove form a support wall 11. In some embodiments, the implant for reducing intraocular pressure further includes a transverse groove 12 extending toward the lower surface 3 of the implant body 1 and arranged on the upper surface of the support wall 11 along the front-to-back direction of the support wall 11, and the transverse groove 12 is connected to the longitudinal drainage groove 4.
[0078] like Figure 7 , Figure 8 , Fig.10 , Fig.11 , Fig.13 , Fig.14 , Fig.16 , Fig.17 , Fig.19 , Fig. 20 , Fig. 22 , Fig.23 , Fig.24 , Fig.25 , Fig.26 , Fig.28As shown, there are two support walls 11, and a plurality of transverse grooves 12 are arranged on each support wall 11, and the plurality of transverse grooves 12 are arranged regularly or irregularly along the front-back direction of the support wall 11. By providing the transverse grooves 12, the friction between the upper surface 2 of the implant body 1 and the sclera 200 can be increased, the displacement of the implant body 1 can be avoided, and the stability of the implant body 1 can be enhanced; at the same time, these transverse grooves 12 are also connected to the longitudinal drainage groove 4, and have the function of diverting aqueous humor, which is also part of the diversion part; the transverse grooves 12 can also reduce the stress on the upper surface of the implant body 1, so that the implant body 1 is easier to bend and fits the sclera 200 more closely.
[0079] like Figure 8 to Figure 13 , Figure 20 to Figure 25 As shown, in some embodiments, the cross-sectional shape of the transverse groove 12 is a trapezoid, such as Figure 7 As shown, in other embodiments, the cross-sectional shape of the transverse groove 12 is semicircular; Fig.14 , Fig.15 , Fig.16 , Fig.26 , Fig. 27 , Fig.28 As shown, in some other embodiments, the cross-sectional shape of the transverse groove 12 can also be a rectangle or other shapes.
[0080] Furthermore, the width of the transverse groove 12 is 0.1-0.4 mm. In some embodiments, the widths of the plurality of transverse grooves 12 may be the same or different.
[0081] The depth of the transverse groove 12 is 0.1 to 0.4 mm. In some embodiments, the depths of multiple transverse grooves 12 may be the same or different. For example, the depth of the transverse groove 12 tends to gradually increase from the front and rear sides of the implant body 1 to the middle part of the implant body 1.
[0082] The number of transverse grooves 12 can be multiple on the supporting walls 11 on both sides of the implant body 1, such as Figure 8 , Fig. 9 , Fig.10 , Fig. 20 , Fig.21 , Fig. 22 As shown, in some embodiments, the number of transverse grooves 12 of the same support wall 11 is 3; Figure 7 , Figures 11 to 16 , Fig.23 , Fig.24 , Figure 25 to Figure 28 As shown, in some other embodiments, the number of the transverse grooves 12 of the same supporting wall 11 is 5. In other embodiments, the number of corresponding transverse grooves 12 can be set according to the longitudinal length of the upper surface 2 of the implant body 1, and is not limited to 3 or 5.
[0083] In some preferred embodiments, the transverse grooves 12 on the support walls 11 on both sides of the implant body 1 are symmetrically arranged, and the bottom of the transverse groove 12 is flush with the bottom of the longitudinal drainage groove 4, which is more conducive to lateral diversion of aqueous humor.
[0084] like Figures 17 to 28 As shown, in some embodiments, the front end of the implant body 1 further extends in a direction away from the rear end of the implant body 1 and bends downward to form a snap-fit portion 13.
[0085] In these embodiments, the rear end face 6 of the implant body 1 is perpendicular to the lower surface 3 of the implant body 1, the front end face 5 of the implant body 1 is parallel to the lower surface 3 of the implant body 1 or there is an angle between the front end face 5 of the implant body 1 and the lower surface 3 of the implant body 1.
[0086] The front end (proximal end) of the implant body 1 is gradually bent downward to form a snap-fitting portion 13. The snap-fitting portion 13 can further avoid the risk of the front end (proximal end) of the implant body 1 contacting the cornea 500 even when the anterior chamber is exposed. At the same time, the arc-shaped snap-fitting portion 13 can be tightly fastened to the root of the iris 400 to prevent the implant body 1 from moving in the distal direction and affecting the choroid 100, thereby avoiding detachment of the choroid 100. At the same time, even if the implant body 1 moves in the proximal direction, it will not cause damage to the corneal endothelial cells. More specifically, in order to make the snap-fitting portion 13 better conform to the physiological curvature of the iris and facilitate anchoring, the snap-fitting portion 13 has a bending radius of curvature of 3 to 6 mm and a chord length of 0.5 to 2.5 mm.
[0087] In addition, in order to increase the bonding force between the implant body 1 and the suprachoroidal ocular tissue and further stabilize the implant after implantation, in the above-mentioned embodiment of the present application or some other embodiments, longitudinal and transverse microgrooves are provided on the surface of the support wall 11 and the lower surface 3 of the implant body 1, so that the sclera and the choroid can further fix the implant body 1 through these microgrooves. Alternatively, in some other embodiments, the implant body 1 is made of porous silica gel, porous polyethylene or porous TPU, with a pore size of 10 to 60 μm and a porosity of 30 to 70%. The use of porous materials can enhance the bonding force between the implant and the ocular tissue on the one hand, and on the other hand, part of the aqueous humor can also flow through its pores to improve the diversion effect.
[0088] Combination Figure 29 to Figure 31In some embodiments, an implant for reducing intraocular pressure includes an implant body 1 and a drainage portion located on the implant body 1, and the drainage portion is used to drain aqueous humor from the anterior chamber to reduce intraocular pressure. In these embodiments, the implant body 1 has a porous structure, the drainage portion includes a porous structure, and the aqueous humor can flow through the pores of the porous structure, thereby draining the aqueous humor from the anterior chamber to reduce intraocular pressure, and the pore size of the porous structure is 10 to 60 μm, and the porosity is 30 to 70%.
[0089] The guide part also includes a longitudinal drainage groove 4 arranged on the upper surface 2 of the implant body 1 along the longitudinal direction of the implant body 1. The implant body 1 can increase the outflow of aqueous humor from the suprachoroidal space 300 through the longitudinal drainage groove 4, has a better drainage effect, is not easy to cause blockage, and further plays a role in reducing intraocular pressure.
[0090] In these embodiments, the implant body 1 is in the shape of a strip, and is implanted as a whole and in the suprachoroidal space 300 along its longitudinal direction. The implant body 1 includes a proximal portion 101, a distal portion 103 and a middle portion 102 in the longitudinal direction. The proximal portion 101 is the end of the implant close to the anterior chamber after the implant is implanted in the eye, and the distal portion 103 is the other end of the implant away from the anterior chamber after the implant is implanted in the eye; the lower surface 3 of the implant body 1 is flat, the upper surface 2 of the implant body 1 is at least partially curved, and the thickness of at least the distal portion 103 to the middle portion 102 of the implant body 1 gradually increases.
[0091] exist Figure 29 to Figure 31 In the embodiment, the upper surface 2 of the implant body 1 includes a plane portion and a curved portion, and the curved portion gradually increases the thickness from the distal portion 103 to the middle portion 102 of the implant body 1. The upper surface of the proximal portion 101 belongs to the plane portion, which is parallel to the lower surface 3 of the implant body 1, while the upper surface of the distal portion 103 belongs to the curved portion. It can be seen that the proximal portion 101 is larger in volume in the longitudinal direction of the implant body 1 relative to the distal portion 103. After implantation in the suprachoroidal space 300, the anterior chamber angle of the eye will be more open, which is more conducive to the circulation of aqueous humor. And because the thickness from the distal portion 103 to the middle portion 102 of the present implant gradually increases, it can also prevent the implant from moving in the distal direction and avoid affecting the choroid 100.
[0092] In addition to the above differences, the implant structure, structural dimensions, materials, etc. of the present implant and other embodiments of the present utility model can be completely the same. For example, in some embodiments, the upper surface of the body of the present implant is also provided with a plurality of transverse grooves 12 as described in other embodiments of the present application, in some embodiments, the longitudinal drainage groove 4 of the present implant is also provided with a flow regulator as described in other embodiments of the present application, in some embodiments, the surface of the support wall 11 and the lower surface 3 of the present implant body 1 are provided with longitudinal and transverse microgrooves as described in other embodiments of the present application, and in some preferred embodiments, the above-mentioned transverse grooves, flow regulators or two or more of the above-mentioned microgrooves can also be provided simultaneously in the present implant.
[0093] Combination Figures 1 to 32 The utility model provides an implant for reducing intraocular pressure, which is used to be implanted in the suprachoroidal space 300 to increase the outflow of aqueous humor from the suprachoroidal space 300 and reduce intraocular pressure. The process of implanting the implant in the suprachoroidal space 300 is as follows:
[0094] Step 1: Making a surgical incision at the edge of the cornea 500;
[0095] Step 2: Inject a certain amount of viscoelastic into the anterior chamber to open the chamber angle;
[0096] Step 3: inserting a delivery device loaded with an implant for reducing intraocular pressure from the surgical incision, and inserting the head end of the delivery device into the suprachoroidal space 300;
[0097] Step 4: Manipulate the handle of the delivery device to release the implant that reduces intraocular pressure;
[0098] Step 5: withdraw the conveyor and extract the viscoelastic agent;
[0099] Step 6: Suturing the surgical incision at the edge of the cornea 500.
[0100] After being implanted in the suprachoroidal space 300, the intraocular pressure reducing implant of the utility model can expand the originally narrow space of the suprachoroidal space 300, increase the outflow of aqueous humor from the suprachoroidal space 300, have a good drainage effect, are not easy to be blocked, and play a role in reducing intraocular pressure. The intraocular pressure reducing implant can be stably attached to the choroid 100, reduce the risk of displacement to the anterior chamber and the choroid 100, avoid exposure to the anterior chamber to touch the cornea, and minimize the risk of corneal endothelial cell loss. In addition, the intraocular pressure reducing implant of the utility model can be performed simultaneously with cataract surgery during the implantation process, share the same surgical incision, and reduce the complexity of the surgical process.
[0101] The above description is only an embodiment of the present invention, and does not limit the patent scope of the present invention. Any equivalent structural transformation made using the contents of the specification and drawings of the present invention, or directly or indirectly applied in other related technical fields, is also included in the patent protection scope of the present invention.
Claims
1. An implant for reducing intraocular pressure, comprising an implant body and a drainage portion located on the implant body, wherein the drainage portion is used to drain aqueous humor from the anterior chamber to reduce intraocular pressure, characterized in that: The implant body is strip-shaped and is used to be longitudinally implanted in the suprachoroidal space. The implant body includes a proximal portion, a distal portion and a middle portion in the longitudinal direction. The proximal portion is the end of the implant close to the anterior chamber after the implant is implanted in the eye. The lower surface of the implant body is flat, and the upper surface of the implant body is at least partially curved, and the thickness of at least the implant body gradually increases from the distal portion to the middle portion.
2. The implant for reducing intraocular pressure according to claim 1, characterized in that The thickness of the distal end and the proximal end of the implant body to the middle part increases gradually, and the upper surface of the implant body is in a convex arch shape as a whole.
3. The implant for reducing intraocular pressure according to claim 1 or 2, characterized in that: The implant body has a porous structure, and the flow guide portion includes the porous structure.
4. The implant for reducing intraocular pressure according to claim 3, characterized in that The pore size of the porous structure is 10-60 μm, and the porosity is 30-70%.
5. The implant for reducing intraocular pressure according to claim 3, characterized in that The guide portion further includes a longitudinal drainage groove arranged on the upper surface of the implant body along the longitudinal direction of the implant body.
6. The implant for reducing intraocular pressure according to claim 5, characterized in that: The parts of the implant body located on both sides of the longitudinal drainage groove form a support wall, and a transverse groove extending toward the lower surface of the implant body is arranged on the upper surface of the support wall along the front-to-back direction of the support wall, and the transverse groove is connected to the longitudinal drainage groove.
7. The implant for reducing intraocular pressure according to claim 6, characterized in that: There are multiple transverse grooves, which are arranged regularly or irregularly along the front-to-back direction of the support wall.
8. The implant for reducing intraocular pressure according to claim 5, characterized in that: There is at least one longitudinal drainage groove, which is arranged at the middle position of the upper surface of the implant body.
9. The implant for reducing intraocular pressure according to claim 5, characterized in that: The width of the longitudinal drainage groove in the transverse direction of the implant body is 0.2-0.6 mm, and the depth of the longitudinal drainage groove is 0.1-0.4 mm.
10. The implant for reducing intraocular pressure according to claim 5, characterized in that: The cross-sectional shape of the longitudinal drainage groove is rectangular or semicircular.
11. The implant for reducing intraocular pressure according to claim 6, characterized in that: The cross-sectional shape of the transverse groove is rectangular, trapezoidal or semicircular.
12. The intraocular pressure reducing implant according to claim 1, characterized in that: The maximum thickness from the upper surface to the lower surface of the implant body is 0.6±0.1 mm; the minimum thickness from the upper surface to the lower surface of the implant body is 0.3±0.1 mm.
13. The intraocular pressure reducing implant according to claim 1, characterized in that: The width of the implant body in the transverse direction is 0.8-1.1 mm; the length of the implant body in the front-back direction is 4-6 mm.
Citation Information
Cited By
Eye implant
CN119499038A
An eye implant
CN119499038B
